Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus

Glansbeek, Harrie L.; Haagmans, Bart L.; Lintelo, Eddie G. te; Egberink, Herman; Duquesne, Véronique; Aubert, André; Horzinek, Marian C.; Rottier, Peter J. M.

doi:10.1099/0022-1317-83-1-1

Cited by 45 publications

(34 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, mixtures of DNA vaccines do not efficiently elicit immune responses as effectively as the same vaccine(s) administered alone [35,84,87]. However, other reports have not shown deleterious effects on the immune response during DNA co-immunizations.…”

Section: Discussionmentioning

confidence: 90%

Reduction of Anti-HIV-1 Gag Immune Responses During Co-Immunization: Immune Interference by the HIV-1 Envelope

Toapanta

Craigo²,

Montelaro³

et al. 2007

CHR

View full text Add to dashboard Cite

Immunization with more than one immunogen (co-immunization) is an efficient regimen to induce immunity to multiple antigens. However, immune interference has been reported using multi-plasmid DNA immunizations. HIV-1 envelope (Env) and Gag gene products are the predominant immunogens used in current AIDS vaccines, although, few studies have evaluated possible immune interference when these two antigens are co-administered. Therefore, in this study, immune interference during co-inoculation was examined using DNA vaccines expressing lentiviral Envs and Gag from gene sequences optimized for efficient expression in mammalian cells (codon-optimized). BALB/c mice vaccinated in separate hind legs with each plasmid individually elicited high titer immune responses, however, when HIV-1 Env(gp120) and HIV-1 Gag(p55) DNA plasmids were co-inoculated, there was a reduction in the immune responses elicited to HIV-1 Gag(p55). To determine if the anti-HIV-1 Gag(p55) immune interference was specific to HIV-1 Env(gp120), mice were co-immunized with plasmids expressing the surface envelope protein from two additional lentiviruses, Env(gp130)-SIV or Env(gp90)-EIAV, or a soluble form of hemagglutinin (sHA) from influenza virus and HIV-1 Gag(p55)- or SIV Gag(p55)-DNA. Interestingly, there was no reduction in anti-HIV-1 Gag(p55) immune responses using other lentiviral envelopes or the influenza sHA. Also, none of the lentiviral envelopes reduced anti-SIV Gag(p55) immune responses during co-immunization. Therefore, anti-HIV-1 Gag immune interference appears specific to co-immunizations with HIV-1 Env(gp120) and may involve a yet undefined immunological mechanism(s).

show abstract

Section: Discussionmentioning

confidence: 90%

Reduction of Anti-HIV-1 Gag Immune Responses During Co-Immunization: Immune Interference by the HIV-1 Envelope

Toapanta

Craigo²,

Montelaro³

et al. 2007

CHR

View full text Add to dashboard Cite

show abstract

“…Specific targeting of skin cells is essential for the delivery of DNA vaccines to cutaneous antigen presenting cells to elicit the local immune response without the systemic toxicity, such as development of systemic auto-immune reactions or modulation of immune response (Glansbeek et al 2002;Schalk et al 2006). So far, different therapeutically relevant plasmids have been transfected to the skin.…”

Section: Localized and Systemic Distribution Of Il-12mentioning

confidence: 99%

Improved Specificity of Gene Electrotransfer to Skin Using pDNA Under the Control of Collagen Tissue-Specific Promoter

et al. 2015

View full text Add to dashboard Cite

In order to ensure safe, efficient and controlled gene delivery to skin, the improvement of delivery methods together with proper design of DNA is required. Non-viral delivery methods, such as gene electrotransfer, and the design of tissue-specific promoters are promising tools to ensure the safety of gene delivery to the skin. In the scope of our study, we evaluated a novel skin-specific plasmid DNA with collagen (COL) promoter, delivered to skin cells and skin tissue by gene electrotransfer. In vitro, we determined the specificity of the COL promoter in fibroblast cells. The specific expression under the control of COL promoter was obtained for the reporter gene DsRed as well as for therapeutic gene encoding cytokine IL-12. In vivo, the plasmid with COL promoter encoding the reporter gene DsRed was efficiently transfected to mouse skin. It resulted in the notable and controlled manner, however, in lower and shorter expression, compared to that obtained with ubiquitous promoter. The concentration of the IL-12 in the skin after the in vivo transfection of plasmid with COL promoter was in the same range as after the treatment in control conditions (injection of distilled water followed by the application of electric pulses). Furthermore, this gene delivery was local, restricted to the skin, without any evident systemic shedding of IL-12. Such specific targeting of skin cells, observed with tissue-specific COL promoter, would improve the effectiveness and safety of cutaneous gene therapies and DNA vaccines.

show abstract

“…IL-12-encoding plasmid enhanced susceptibility to a challenge with feline infectious peritonitis virus (FIPV). 51 Infection of mice that were genetically resistant to infection by ectromelia virus (a mouse pox virus) with an IL-4-expressing ectromelia virus caused high mortality rates. Also infection of immunized, resistant mice with this IL-4-expressing ectromelia recombinant virus caused substantial mortality, probably caused by suppression of cytotoxic T-lymphocyte cytolytic activity and inhibition of memory responses.…”

Section: Environmental Spreadmentioning

confidence: 99%

Preclinical and Clinical Safety Studies on DNA Vaccines

Schalk¹,

Mooi²,

Berbers³

et al. 2006

Human Vaccines

114

View full text Add to dashboard Cite

DNA vaccines are based on the transfer of genetic material, encoding an antigen, to the cells of the vaccine recipient. Despite high expectations of DNA vaccines as a result of promising preclinical data their clinical utility remains unproven. However, much data is gathered in preclinical and clinical studies about the safety of DNA vaccines. Here we review current knowledge about the safety of DNA vaccines. Safety concerns of DNA vaccines relate to genetic, immunologic, toxic, and environmental effects. In this review we provide an overview of findings related to the safety of DNA vaccines, obtained so far. We conclude that the potential risks of DNA vaccines are minimal. However, their safety issues may differ case-by-case, and they should be treated accordingly.

show abstract

Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus

Cited by 45 publications

References 50 publications

Reduction of Anti-HIV-1 Gag Immune Responses During Co-Immunization: Immune Interference by the HIV-1 Envelope

Reduction of Anti-HIV-1 Gag Immune Responses During Co-Immunization: Immune Interference by the HIV-1 Envelope

Improved Specificity of Gene Electrotransfer to Skin Using pDNA Under the Control of Collagen Tissue-Specific Promoter

Preclinical and Clinical Safety Studies on DNA Vaccines

Contact Info

Product

Resources

About